APA (7th ed.) Citation

Emens, L. A., Adams, S., Barrios, C. H., Diéras, V., Iwata, H., Loi, S., . . . Schmid, P. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of oncology, 32(8), . https://doi.org/10.1016/j.annonc.2021.05.355

Chicago Style (17th ed.) Citation

Emens, Leisha Ann, et al. "First-line Atezolizumab Plus Nab-paclitaxel for Unresectable, Locally Advanced, or Metastatic Triple-negative Breast Cancer: IMpassion130 Final Overall Survival Analysis." Annals of Oncology 32, no. 8 (2021). https://doi.org/10.1016/j.annonc.2021.05.355.

MLA (9th ed.) Citation

Emens, Leisha Ann, et al. "First-line Atezolizumab Plus Nab-paclitaxel for Unresectable, Locally Advanced, or Metastatic Triple-negative Breast Cancer: IMpassion130 Final Overall Survival Analysis." Annals of Oncology, vol. 32, no. 8, 2021, https://doi.org/10.1016/j.annonc.2021.05.355.